Trevi Therapeutics Participation in Major Forum
Trevi Therapeutics, Inc. (NASDAQ: TRVI), a clinical-stage biopharmaceutical company, is gearing up to participate in an important event for the biopharmaceutical community. The company’s President and Chief Executive Officer, Jennifer Good, alongside Chief Financial Officer, Lisa Delfini, will be attending the Learink Partners Therapeutics Forum: I&I and Metabolism. This forum, scheduled for a couple of days, serves as a pivotal gathering for professionals engaged in innovative therapeutic developments.
Introducing Haduvio™ for Chronic Cough
At the forefront of Trevi Therapeutics' agenda is Haduvio™ (oral nalbuphine ER), an investigational therapy designed specifically to address chronic cough in patients suffering from idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). This therapy takes a unique approach to the cough reflex by acting on both central and peripheral receptors as a kappa agonist and a mu antagonist (KAMA). It's noteworthy that Haduvio is the first investigational drug shown to significantly reduce cough frequency in clinical trials targeting these patient groups.
Understanding Chronic Cough and Its Impact
Chronic cough represents a prevalent concern, particularly among patients grappling with IPF, where it affects a staggering 85% of individuals diagnosed. In the U.S., about 150,000 patients are living with IPF, and the nature of chronic cough can severely impact daily life, with patients experiencing coughs that may occur up to 1,500 times each day. Such relentless coughing not only deteriorates physical health but can also lead to significant emotional and social challenges.
Refractory Chronic Cough – A Growing Concern
Refractory chronic cough presents an even more daunting challenge as it lacks approved treatment options within the U.S. Defined as a persistent cough lasting longer than eight weeks despite other treatments, RCC affects around 2 to 3 million patients nationally. The condition stems from heightened sensitivity of the cough reflex, which can arise from various underlying issues such as asthma and chronic bronchitis. Its debilitating effects often extend beyond health, leading to adverse social and economic consequences.
Regulatory Status and Future Outlook
While Trevi plans to propose the trade name Haduvio for oral nalbuphine ER, it's essential to acknowledge that the safety and efficacy of this therapy are currently under evaluation, and no regulatory body has formally assessed it yet. The company is optimistic about its potential to fill a critical gap in treatment options for chronic cough sufferers.
About Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc. is dedicated to developing innovative therapies that can address unmet medical needs, particularly for conditions with significant patient burdens. The company continuously strives to improve the quality of life for patients affected by chronic cough and other debilitating conditions.
Frequently Asked Questions
What is Trevi Therapeutics, Inc. known for?
Trevi Therapeutics, Inc. specializes in developing therapies for chronic cough, especially for patients with idiopathic pulmonary fibrosis and refractory chronic cough.
What is Haduvio™?
Haduvio™ is an investigational oral therapy being developed to reduce chronic cough frequencies in patients with specific cough-related conditions.
What role does Trevi's CEO have in upcoming events?
The CEO, Jennifer Good, will be participating in the Leerink Partners Therapeutics Forum to discuss the company's advancements and projects.
Is there any treatment available for chronic cough?
Currently, there are no approved therapies for chronic cough in IPF patients, and existing off-label options offer limited benefits.
What is the current status of Haduvio™?
Haduvio™ has not yet received approval from any regulatory authority, and its safety and efficacy are under investigation.
